Genomic Classification and Prognosis in Acute Myeloid Leukemia

Cited by (1,007)

Items 101–200 of 1,007

1. The epigenomics of sarcoma
   Benjamin Alexander Nacev, Kevin B. Jones, Andrew M. Intlekofer, Jamie Yu, C. David Allis, William D. Tap, Marc Ladanyi, Torsten O. Nielsen · 2020 · Nature reviews. Cancer
2. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
   Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi, Rouzbeh Chegeni, Majid Safa · 2021 · Journal of Hematology & Oncology
3. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
   Sung E. Choe, Hongfang Wang, Courtney Denton Dinardo, Eytan M. Stein, Stéphane de Botton, Gail J. Roboz, Jessica Kaplan Altman, Alice S. Mims, Justin M. Watts, Daniel Aaron Pollyea et al. · 2020 · Blood Advances
4. Biological and clinical consequences of NPM1 mutations in AML
   Emily M. Heath, Steven M. Chan, Mark David Minden, Tracy Murphy, Liran I. Shlush, Aaron David Schimmer · 2017 · Leukemia
5. Subtype-specific 3D genome alteration in acute myeloid leukaemia
   Xu, Jie, Song, Fan, Lyu, Huijue, Kobayashi, Mikoto, Zhang, Baozhen, Zhao, Ziyu, Hou, Ye, Wang, Xiaotao, Luan, Yu, Jia, Bei et al. · 2022 · Nature
6. Machine learning and feature selection for drug response prediction in precision oncology applications
   Mehreen Ali, Tero A. Aittokallio · 2018 · Biophysical Reviews
7. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia
   Haijiao Zhang, Yusuke Nakauchi, Thomas Köhnke, Melissa Stafford, Daniel Bottomly, Rozario Thomas, Beth Wilmot, Shannon K. McWeeney, Ravindra Majeti, Jeffrey W Tyner · 2020 · Nature Cancer
8. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
   Vanessa Elaine Kennedy, Catherine Choy Smith · 2020 · Frontiers in Oncology
9. Isocitrate Dehydrogenase Mutation and ( R )-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development
   Dang, Lenny, Su, Shin-San Michael · 2017 · Annual Review of Biochemistry
10. A review of FLT3 inhibitors in acute myeloid leukemia
    Jennifer C. Zhao, Sonal Agarwal, Hiba Ahmad, Kejal Amin, Jan Philipp Bewersdorf, Amer Methqal Zeidan · 2021 · Blood Reviews
11. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
    Dyantha I. van der Lee, Rogier M. Reijmers, Maria W. Honders, Renate S. Hagedoorn, Rob C. M. de Jong, Michel G.D. Kester, Dirk M. van der Steen, Arnoud H. de Ru, Christiaan Kweekel, Helena M. Bijen et al. · 2019 · Journal of Clinical Investigation
12. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
    Niccolò Bolli, Giulia Biancon, Matahi Moarii, Silvia Gimondi, Yilong Li, Chiara De Philippis, Francesco Maura, Vijitha Sathiaseelan, Yu‐Tzu Tai, Laura J. Mudie et al. · 2017 · Leukemia
13. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
    Ronan T. Swords, Steven E. Coutre, Michael B. Maris, Joshua F. Zeidner, James M. Foran, Jose Carlos Cruz, Harry Paul Erba, Jesús G. Berdeja, Wayne Tam, Saran Vardhanabhuti et al. · 2018 · Blood
14. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
    Ghayas C. Issa, Courtney Denton Dinardo · 2021 · Blood Cancer Journal
15. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
    Konstanze Döhner, Christian Thiede, Nikolaus Jahn, Ekaterina Panina, Agnes Gambietz, Richard A. Larson, Thomas W. Prior, Guido Marcucci, Dan M. Jones, Jürgen Krauter et al. · 2019 · Blood
16. Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia
    Chau‐To Kwok, Amy D. Marshall, John E.J. Rasko, Justin J. -L. Wong · 2017 · Journal of Hematology & Oncology
17. Clonal evolution of colorectal cancer in IBD
    Chang-Ho Ryan Choi, Ibrahim Al Bakir, Ailsa L Hart, Trevor A. Graham · 2017 · Nature Reviews Gastroenterology & Hepatology
18. Therapeutic implications of menin inhibition in acute leukemias
    Ghayas C. Issa, Farhad Ravandi, Courtney Denton Dinardo, Elias Joseph Jabbour, Hagop M. Kantarjian, Michael Andreeff · 2021 · Leukemia
19. Unified classification and risk-stratification in Acute Myeloid Leukemia
    Yanis Tazi, Juan Arango Ossa, Yangyu Zhou, Elsa Bernard, Ian Thomas, Amanda Gilkes, Sylvie D. Freeman, Yoann Pradat, Sean J. Johnson, Robert Kerrin Hills et al. · 2022 · Nature Communications
20. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
    Malani, Disha, Kumar, Ashwini, Brück, Oscar, Kontro, Mika, Yadav, Bhagwan, Hellesøy, Monica, Kuusanmäki, Heikki, Dufva, Olli, Kankainen, Matti, Eldfors, Samuli et al. · 2022 · Cancer Discovery
21. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
    Lynn Swun Quek, Muriel D. David, Alison Kennedy, Marlen Metzner, Michael D. Amatangelo, Alan H. Shih, Bilyana Stoilova, Cyril Quivoron, Maël Heiblig, Christophe Willekens et al. · 2018 · Nature Medicine
22. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
    Tobias Herold, Maja Rothenberg‐Thurley, Victoria V. Grunwald, Hanna Janke, Dennis Görlich, Maria Cristina Sauerland, Nikola P. Konstandin, Annika Maria Dufour, Stephanie E. Schneider, Michaela Neusser et al. · 2020 · Leukemia
23. Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome
    Alyssa L. Kennedy, Kasiani C. Myers, James R. Bowman, Christopher James Gibson, Nicholas D. Camarda, Elissa Furutani, Gwen M. Muscato, Robert H. Klein, Kaitlyn Ballotti, Shanshan Liu et al. · 2021 · Nature Communications
24. Potential Mechanisms of Action for Vitamin C in Cancer: Reviewing the Evidence
    Vissers, Margreet C. M., Das, Andrew B. · 2018 · Frontiers in Physiology
25. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
    Amy L. Burd, Ross L. Levine, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Prapti Arvind Patel, Maria R. Baer, Wendy Stock, Michael W. Deininger et al. · 2020 · Nature Medicine
26. Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence
    Allison L. Boyd, Lili Aslostovar, Jennifer C. Reid, Wenqing Ye, Borko Tanasijevic, Deanna P. Porras, Zoya Shapovalova, Mohammed Almakadi, Ronan Foley, Brian F. Leber et al. · 2018 · Cancer Cell
27. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach
    Hagop M. Kantarjian, Tapan Mahendra Kadia, Courtney Denton Dinardo, Mary Alma Welch, Farhad Ravandi · 2021 · Cancer
28. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis
    Masayuki Yamashita, Paul V. Dellorusso, Oakley C. Olson, Emmanuelle A. Passegue · 2020 · Nature reviews. Cancer
29. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
    Kiyomi Morita, Hagop M. Kantarjian, Feng Wang, Yuanqing Yan, Carlos Bueso-Ramos, Koji Sasaki, Ghayas C. Issa, Sa Wang, Jeffrey L. Jorgensen, Xingzhi Song et al. · 2018 · Journal of Clinical Oncology
30. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
    Courtney Denton Dinardo, Anthony Selwyn Stein, Eytan M. Stein, Amir Tahmasb Fathi, Olga Frankfurt, Andre C. Schuh, Hartmut Döhner, Giovanni Martinelli, Prapti Arvind Patel, Emmanuel Raffoux et al. · 2020 · Journal of Clinical Oncology
31. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma
    Yoichi Robertus Fujii, Yusuke Sato, Hiromichi Suzuki, Nobuyuki Kakiuchi, Tetsuichi Yoshizato, Andrew Thomas Lenis, Shigekatsu Maekawa, Akira Yokoyama, Yasuhide Takeuchi, Yoshikage Inoue et al. · 2021 · Cancer Cell
32. Subtype-specific regulatory network rewiring in acute myeloid leukemia
    Assi, Salam A., Imperato, Maria Rosaria, Coleman, Daniel J. L., Pickin, Anna, Potluri, Sandeep, Ptasinska, Anetta, Chin, Paulynn Suyin, Blair, Helen, Cauchy, Pierre, James, Sally R. et al. · 2019 · Nature Genetics
33. Aberrant RNA Splicing in Cancer and Drug Resistance
    Bi‐Dar Wang, Norman Lee · 2018 · Cancers
34. Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin
    Laura Katharina Schmalbrock, Anna Dolnik, Sibylle Cocciardi, Eric Sträng, Frauke Theis, Nikolaus Jahn, Ekaterina Panina, Tamara J. Blätte, Julia Herzig, Sabrina Skambraks et al. · 2021 · Blood
35. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
    German-Austrian AML Study Group (AMLSG), Gabriele Nagel, Daniela Weber, Ella Fromm, S. Erhardt, Michael Lübbert, Walter Fiedler, Thomas Kindler, J. Krauter, Peter Brossart et al. · 2017 · Annals of Hematology
36. Genetics of progression from MDS to secondary leukemia
    Andrew J. Menssen, Matthew J. Walter · 2020 · Blood
37. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
    Evan M. Cherry, Diana Abbott, Maria L. Amaya, Christine M. McMahon, Marc Schwartz, Julie A. Rosser, Audrey Sato, Jeffrey T. Schowinsky, Anagha Inguva Sheth, Mohd Minhajuddin et al. · 2021 · Blood Advances
38. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
    Donia M. Moujalled, Giovanna Pomilio, Corina Ghiurau, Adam Ivey, Jessica M. Salmon, Sewa Rijal, Sarah MacRaild, Lan Zhang, Tse‐Chieh Teh, Ing Soo Tiong et al. · 2018 · Leukemia
39. Causes and consequences of clonal hematopoiesis
    Weeks, Lachelle D., Ebert, Benjamin L. · 2023 · Blood
40. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
    Tracy Murphy, Karen W L Yee · 2017 · Expert Opinion on Pharmacotherapy
41. The clinical impact of the molecular landscape of acute myeloid leukemia
    Sabine Käyser, Mark J. Levis · 2023 · Haematologica
42. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
    Hartmut Döhner, Keith William Pratz, Courtney Denton Dinardo, Andrew H. Wei, Brian Andrew Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu et al. · 2024 · Blood
43. Genomic Classification in Acute Myeloid Leukemia
    Elli Papaemmanuil, Hartmut Döhner, Peter J Campbell · 2016 · New England Journal of Medicine
44. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy
    Miron Prokocimer, Alina Molchadsky, Varda Rotter · 2017 · Blood
45. Advances in understanding of angioimmunoblastic T-cell lymphoma
    Shigeru Chiba, Mamiko Sakata‐Yanagimoto · 2020 · Leukemia
46. Metabolic Plasticity of Acute Myeloid Leukemia
    Johanna Kreitz, Christine Schönfeld, Marcel Seibert, Verena Stolp, Islam Alshamleh, Thomas Oellerich, Björn Steffen, Harald Schwalbe, Frank Schnütgen, Nina Kurrle et al. · 2019 · Cells
47. Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax
    Kim, Kunhwa, Maiti, Abhishek, Loghavi, Sanam, Pourebrahim, Rasoul, Kadia, Tapan M., Rausch, Caitlin R., Furudate, Ken, Daver, Naval G., Alvarado, Yesid, Ohanian, Maro et al. · 2021 · Cancer
48. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
    T-C Teh, N-Y Nguyen, Donia M. Moujalled, David Segal, Giovanna Pomilio, Sewa Rijal, Anissa M. Jabbour, Katherine D. Cummins, Kurt Lackovic, Piers A. Blombery et al. · 2017 · Leukemia
49. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma
    Keisuke Kataoka, Masako Iwanaga, Jun‐ichirou Yasunaga, Yasunobu Nagata, Akira Kitanaka, Takuro Kameda, Makoto Yoshimitsu, Yuichi Shiraishi, Aiko Sato‐Otsubo, Masashi Sanada et al. · 2017 · Blood
50. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
    Curtis Andrew Lachowiez, Sanam Loghavi, Tapan Mahendra Kadia, Naval Guastad Daver, Gautam M. Borthakur, Naveen Pemmaraju, Kiran Naqvi, Yesid Alvarado, Musa E. Yilmaz, Nicholas James Short et al. · 2020 · Blood Advances
51. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution
    Rodriguez-Meira, Alba, Norfo, Ruggiero, Wen, Sean, Chédeville, Agathe L., Rahman, Haseeb, O’Sullivan, Jennifer, Wang, Guanlin, Louka, Eleni, Kretzschmar, Warren W., Paterson, Aimee et al. · 2023 · Nature Genetics
52. CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
    Ugo Testa, Elvira Pelosi, Germana Castelli · 2019 · Cancers
53. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
    Elihu H. Estey, Robert Paul Hasserjian, Hartmut Döhner · 2021 · Blood
54. Identification of Stem Cells in the Epithelium of the Stomach Corpus and Antrum of Mice
    Junichi Matsuo, Shunichi Kimura, Akihiro Yamamura, Cai Ping Koh, Md Zakir Hossain, Dede Liana Heng, Kazuyoshi Kohu, Dominic Chih‐Cheng Voon, Hiroshi Hiai, Michiaki Unno et al. · 2016 · Gastroenterology
55. UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs
    Malgorzata Gozdecka, Eshwar Meduri, Milena M. Mazan, Konstantinos Tzelepis, Monika Dudek, Andrew J. Knights, Mercedes Pardo, Lu Yu, Jyoti S. Choudhary, Emmanouil Metzakopian et al. · 2018 · Nature Genetics
56. The proteogenomic subtypes of acute myeloid leukemia
    Ashok Kumar Jayavelu, Sebastian Wolf, Florian Buettner, Gabriela Alexe, Björn Häupl, Federico Comoglio, Constanze Schneider, Carmen Doebele, Dominik Christian Fuhrmann, Sebastian Wagner et al. · 2022 · Cancer Cell
57. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
    Jayakumar Narayanan Vadakekolathu, Catherine Lai, Stephen Reeder, SE Church, Tressa Hood, Anbarasu Lourdusamy, Michael P. Rettig, Ibrahim Taha Aldoss, Anjali S. Advani, John E. Godwin et al. · 2020 · Blood Advances
58. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models
    Waleed Minzel, Avanthika Venkatachalam, Avner Fink, Eric Hung, Guy Brachya, Ido Burstain, Maya Shaham, Amitai Rivlin, Itay Omer, Adar Zinger et al. · 2018 · Cell
59. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
    Richard Thomas Maziarz, Mark J. Levis, Mrinal M. Patnaik, Bart Lee Scott, Sanjay Ram Mohan, Abhinav Deol, Scott D. Rowley, Dennis Dong Hwan Kim, Daniela Hernandez, Trivikram Rajkhowa et al. · 2020 · Bone Marrow Transplantation
60. Genomic subtyping and therapeutic targeting of acute erythroleukemia
    Iacobucci, Ilaria, Wen, Ji, Meggendorfer, Manja, Choi, John K., Shi, Lei, Pounds, Stanley B., Carmichael, Catherine L., Masih, Katherine E., Morris, Sarah M., Lindsley, R. Coleman et al. · 2019 · Nature Genetics
61. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia
    Audrey Lasry, Bettina Nadorp, Maarten W.J. Fornerod, Deedra Nicolet, Huiyun Wu, Christopher James Walker, Zhengxi Sun, Matthew T. Witkowski, Anastasia N. Tikhonova, María Guillamot et al. · 2022 · Nature Cancer
62. Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history
    Jean Donadieu, Blandine Beaupain, Odile Fenneteau, Christine Bellanné‐Chantelot · 2017 · British Journal of Haematology
63. Pharmacologic inhibition of STAT5 in acute myeloid leukemia
    Bettina Wingelhofer, Barbara Maurer, Elizabeth C. Heyes, Abbarna A. Cumaraswamy, Angelika Berger‐Becvar, Elvin D. de Araujo, Anna Orlova, Patricia Freund, Frank Ruge, Jisung Park et al. · 2018 · Leukemia
64. Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms
    Adam Samuel Sperling, Veronica A. Guerra, James A. Kennedy, Yuanqing Yan, Joanne I. Hsu, Feng Wang, Andrew T. Nguyen, Peter Grant Miller, Marie Ellen McConkey, Vanessa A. Quevedo Barrios et al. · 2022 · Blood
65. Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia
    Tim Grob, Mathijs Arnoud Sanders, Christian M. Vonk, F. G. Kavelaars, Melissa Rijken, Diana Hanekamp, Patrycja L. Gradowska, Jacqueline J Cloos, Yngvar Fløisand, Marinus van Marwijk Kooy et al. · 2022 · Journal of Clinical Oncology
66. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant
    Laura Williams Dillon, Gege Gui, Kristin M. Page, Niveditha Ravindra, Zoë C. Wong, Georgia M. Andrew, Devdeep Mukherjee, Scott L. Zeger, Firas El Chaer, Stephen R. Spellman et al. · 2023 · JAMA
67. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML
    Anna L Brown, Peer Arts, Catherine Carmichael, Milena Babic, Julia Dobbins, Chan‐Eng Chong, ANDREAS W. SCHREIBER, Jinghua Feng, Kerry D. Phillips, Paul Po-Shen Wang et al. · 2020 · Blood Advances
68. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
    Haijiao Zhang, Samantha L. Savage, Anna Reister Schultz, Daniel Bottomly, Libbey White, Erik Segerdell, Beth Wilmot, Shannon K. McWeeney, Christopher A. Eide, Tamilla Nechiporuk et al. · 2019 · Nature Communications
69. Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
    Brenda Chyla, Naval Guastad Daver, Kelly J. Doyle, Evelyn Mary McKeegan, Xin Huang, Vivian R. Ruvolo, Zixing Wang, Ken Chen, Andrew James Souers, Joel D. Leverson et al. · 2018 · American Journal of Hematology
70. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Mishra, Asmita, Tamari, Roni, DeZern, Amy E., Byrne, Michael T., Gooptu, Mahasweta, Chen, Yi-Bin, Deeg, H. Joachim, Sallman, David, Gallacher, Phillip, Wennborg, Anders et al. · 2022 · Journal of Clinical Oncology
71. Emerging therapies for acute myeloid leukemia
    Caner Saygin, Hetty E. Carraway · 2017 · Journal of Hematology & Oncology
72. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia
    Andriana G. Kotini, Chan-Jung Chang, Arthur Chow, Han Yuan, Tzu‐Chieh Ho, Tiansu Wang, Shailee Vora, Alexander Solovyov, Chrystel Husser, Malgorzata Olszewska et al. · 2017 · Cell stem cell
73. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers
    Glass, Jacob L., Hassane, Duane, Wouters, Bas J., Kunimoto, Hiroyoshi, Avellino, Roberto, Garrett-Bakelman, Francine E., Guryanova, Olga A., Bowman, Robert, Redlich, Shira, Intlekofer, Andrew M. et al. · 2017 · Cancer Discovery
74. A Comprehensive Updated Review on Magnetic Nanoparticles in Diagnostics
    Pedro F. Farinha, João M. P. Coelho, Catarina Pinto Reis, Maria Manuela Gaspar · 2021 · Nanomaterials
75. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis
    Ryunosuke Saiki, Yukihide Momozawa, Yasuhito Nannya, Masahiro Marshall Nakagawa, Yotaro Ochi, Tetsuichi Yoshizato, Chikashi Terao, Yutaka Kuroda, Yuichi Shiraishi, Kenichi Chiba et al. · 2021 · Nature Medicine
76. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients
    Friederike Christen, Kaja Hoyer, Kenichi Yoshida, Hsin‐An Hou, Nils Waldhüter, Michael Heuser, Robert Kerrin Hills, Willy Chan, Raphael Hablesreiter, Olga Blau et al. · 2019 · Blood
77. Integrated Informatics Analysis of Cancer-Related Variants
    Kymberleigh A. Pagel, Rick Kim, Kyle Moad, Ben Busby, Lily Zheng, Collin J. Tokheim, Michaël Ryan, Rachel Karchin · 2020 · JCO Clinical Cancer Informatics
78. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
    Ali A. Bazarbachi, Gesine Bug, Frédéric Baron, Éolia Brissot, Fabio Ciceri, Iman Abou Dalle, Hartmut Döhner, Jordi Esteve, Yngvar Fløisand, Sebastian Giebel et al. · 2020 · Haematologica
79. Current status and research directions in acute myeloid leukemia
    Hagop M. Kantarjian, Gautam M. Borthakur, Naval Guastad Daver, Courtney Denton Dinardo, Ghayas C. Issa, Elias Joseph Jabbour, Tapan Mahendra Kadia, Koji Sasaki, Nicholas James Short, Musa E. Yilmaz et al. · 2024 · Blood Cancer Journal
80. A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia
    Tobias Herold, Vindi Jurinović, Aarif M.N. Batcha, Stefanos A. Bamopoulos, Maja Rothenberg‐Thurley, Bianka Ksienzyk, Luise Hartmann, Philipp A. Greif, Julia Philippou‐Massier, Stefan Krebs et al. · 2017 · Haematologica
81. Engaging chromatin: PRC2 structure meets function
    Paul Chammas, Ivano Mocavini, Luciano Di Croce · 2019 · British Journal of Cancer
82. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1 -Mutated Myeloid Malignancies
    Curtis Andrew Lachowiez, Sanam Loghavi, Zhihong Zeng, Tomoyuki N. Tanaka, Yi June Kim, Hidetaka Uryu, Sven Turkalj, Niels Asger Jakobsen, Marlise Rachael Luskin, Dzifa Y. Duose et al. · 2023 · Blood Cancer Discovery
83. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
    Justin Guinney, Tao Wang, Teemu D. Laajala, Kimberly Kanigel Winner, J Christopher Bare, Elias Chaibub Neto, Suleiman A. Khan, Gopal Peddinti, Antti Airola, Tapio Pahikkala et al. · 2016 · The Lancet Oncology
84. The Role of Reactive Oxygen Species in Acute Myeloid Leukaemia
    Jonathan R. Sillar, Zacary P. Germon, Geoffry Nunzio De Iuliis, Matthew D. Dun · 2019 · International Journal of Molecular Sciences
85. Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics
    Lars Velten, Benjamin A. Story, Pablo Hernández-Malmierca, Simon Raffel, Daniel R. Leonce, Jennifer H. Milbank, Malte S. Paulsen, Aykut Demir, Chelsea Szu‐Tu, Robert Frömel et al. · 2021 · Nature Communications
86. Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia
    Hannah J. Uckelmann, Elena L. Haarer, Reina Takeda, Eric M. C. Wong, Charlie Hatton, Christian Marinaccio, Florian Perner, Masooma Rajput, Noa J.C. Antonissen, Yanhe Wen et al. · 2022 · Cancer Discovery
87. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use
    Ulrike Bacher, Evgenii Shumilov, Johanna Flach, Naomi Azur Porret, Raphael Joncourt, Gertrud Wiedemann, Martin Fiedler, Urban Novak, Ursula Amstutz, Thomas Pabst · 2018 · Blood Cancer Journal
88. Emerging roles of spliceosome in cancer and immunity
    Hui Yang, Bruce Beutler, Duanwu Zhang · 2021 · Protein & Cell
89. The Graft-Versus-Leukemia Effect in AML
    Connor Sweeney, Paresh Vyas · 2019 · Frontiers in Oncology
90. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition
    Margarita M. Dzama, Marlene Steiner, Johanna Rausch, Daniel Sasca, Jonas Schönfeld, Kerstin Kunz, Martha C. Taubert, Gerard M. McGeehan, Chun-Wei David Chen, Annalisa Mupo et al. · 2020 · Blood
91. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
    Hartmut Döhner, Anna Dolnik, Lin Tang, John Francis Seymour, Mark David Minden, Richard Maury Stone, Teresa Bernal, Haifa Kathrin Al‐Ali, Valeria Santini, Paresh Vyas et al. · 2018 · Leukemia
92. Landscape and function of multiple mutations within individual oncogenes
    Yuki Saito, Junji Koya, Mitsugu Araki, Yasunori Kogure, Sumito Shingaki, Mariko Tabata, Marni B. McClure, Kota Yoshifuji, Shigeyuki Matsumoto, Yuta Isaka et al. · 2020 · Nature
93. MRD in AML: The Role of New Techniques
    Maria Teresa Voso, Tiziana Ottone, Serena Lavorgna, Adriano Venditti, Luca Maurillo, Francesco Lo‐Coco, Francesco Buccisano · 2019 · Frontiers in Oncology
94. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
    Lucille Stuani, Marie Sabatier, Feng Wang, Nathalie Poupin, Claudie Bosc, Estelle Saland, Florence Anne Castelli, Lara Gales, Camille Montersino, Emeline Boët et al. · 2021 · The Journal of Experimental Medicine
95. Current status and future perspectives in targeted therapy of NPM1-mutated AML
    Roberta Ranieri, Giulia Pianigiani, Sofia Sciabolacci, Vincenzo Maria Perriello, Andrea Marra, Valeria Cardinali, Sara Pierangeli, Francesca Milano, Ilaria Gionfriddo, Lorenzo Brunetti et al. · 2022 · Leukemia
96. Pathophysiology of Acute Myeloid Leukemia
    Franziska Wachter, Yana Pikman · 2024 · Acta Haematologica
97. Acute myeloid leukemia management and research in 2025
    Hagop M. Kantarjian, Courtney Denton Dinardo, Tapan Mahendra Kadia, Naval Guastad Daver, Jessica Kaplan Altman, Eytan M. Stein, Elias Joseph Jabbour, Charles A. Schiffer, Amy M. Lang, Farhad Ravandi · 2024 · CA A Cancer Journal for Clinicians
98. Splicing factor gene mutations in hematologic malignancies
    Borja Sáez, Matthew J. Walter, Timothy Aaron Graubert · 2016 · Blood
99. FLT3–ITD and its current role in acute myeloid leukaemia
    Francisco Alejandro Lagunas‐Rangel, Venice Chávez‐Valencia · 2017 · Medical Oncology
100. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
     Nicole Ali McNeer, John Philip, Heather M. Geiger, Rhonda E. Ries, Vincent‐Philippe Lavallée, Michael Francis Walsh, Minita J. Shah, Kanika S. Arora, Anne‐Katrin Emde, Nicolas Robine et al. · 2019 · Leukemia